Literature DB >> 33925480

NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia.

Vincenza Barresi1, Virginia Di Bella1, Nellina Andriano2,3, Anna Provvidenza Privitera1, Paola Bonaccorso2,3, Manuela La Rosa2,3, Valeria Iachelli2,3, Giorgia Spampinato1, Giulio Pulvirenti2,3, Chiara Scuderi1, Daniele F Condorelli1, Luca Lo Nigro2,3.   

Abstract

Conventional chemotherapy for acute myeloid leukemia regimens generally encompass an intensive induction phase, in order to achieve a morphological remission in terms of bone marrow blasts (<5%). The majority of cases are classified as Primary Induction Response (PIR); unfortunately, 15% of children do not achieve remission and are defined Primary Induction Failure (PIF). This study aims to characterize the gene expression profile of PIF in children with Acute Myeloid Leukemia (AML), in order to detect molecular pathways dysfunctions and identify potential biomarkers. Given that NUP98-rearrangements are enriched in PIF-AML patients, we investigated the association of NUP98-driven genes in primary chemoresistance. Therefore, 85 expression arrays, deposited on GEO database, and 358 RNAseq AML samples, from TARGET program, were analyzed for "Differentially Expressed Genes" (DEGs) between NUP98+ and NUP98-, identifying 110 highly confident NUP98/PIF-associated DEGs. We confirmed, by qRT-PCR, the overexpression of nine DEGs, selected on the bases of the diagnostic accuracy, in a local cohort of PIF patients: SPINK2, TMA7, SPCS2, CDCP1, CAPZA1, FGFR1OP2, MAN1A2, NT5C3A and SRP54. In conclusion, the integrated analysis of NUP98 mutational analysis and transcriptome profiles allowed the identification of novel putative biomarkers for the prediction of PIF in AML.

Entities:  

Keywords:  NUP98-rearrangements; acute myeloid leukemia; chemotherapy resistance; dysregulated genes; omics technologies; transcriptome profile

Year:  2021        PMID: 33925480     DOI: 10.3390/ijms22094575

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  48 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Organization and sequence of the gene encoding the human acrosin-trypsin inhibitor (HUSI-II).

Authors:  A Möritz; K H Grzeschik; E Wingender; E Fink
Journal:  Gene       Date:  1993-01-30       Impact factor: 3.688

3.  The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

Authors:  Hamid Bolouri; Jason E Farrar; Timothy Triche; Rhonda E Ries; Emilia L Lim; Todd A Alonzo; Yussanne Ma; Richard Moore; Andrew J Mungall; Marco A Marra; Jinghui Zhang; Xiaotu Ma; Yu Liu; Yanling Liu; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro C Hermida; Bodour Salhia; Stephen Capone; Giridharan Ramsingh; Christian Michel Zwaan; Sanne Noort; Stephen R Piccolo; E Anders Kolb; Alan S Gamis; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

4.  Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.

Authors:  Fiona C Brown; Paolo Cifani; Esther Drill; Jie He; Eric Still; Shan Zhong; Sohail Balasubramanian; Dean Pavlick; Bahar Yilmazel; Kristina M Knapp; Todd A Alonzo; Soheil Meshinchi; Richard M Stone; Steven M Kornblau; Guido Marcucci; Alan S Gamis; John C Byrd; Mithat Gonen; Ross L Levine; Alex Kentsis
Journal:  Br J Haematol       Date:  2016-10-21       Impact factor: 6.998

5.  NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.

Authors:  J D E de Rooij; I H I M Hollink; S T C J M Arentsen-Peters; J F van Galen; H Berna Beverloo; A Baruchel; J Trka; D Reinhardt; E Sonneveld; M Zimmermann; T A Alonzo; R Pieters; S Meshinchi; M M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Leukemia       Date:  2013-03-27       Impact factor: 11.528

6.  Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients.

Authors:  W-C Chou; C-Y Chen; H-A Hou; L-I Lin; J-L Tang; M Yao; W Tsay; B-S Ko; S-J Wu; S-Y Huang; S-C Hsu; Y-C Chen; Y-N Huang; M-H Tseng; C-F Huang; H-F Tien
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

7.  NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.

Authors:  Hyun Sub Cheong; Youngil Koh; Kwang-Sung Ahn; Chansu Lee; Hyoung Doo Shin; Sung-Soo Yoon
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

Review 8.  Treatment of refractory and relapsed acute myelogenous leukemia.

Authors:  Slobodan Stanisic; Matt Kalaycio
Journal:  Expert Rev Anticancer Ther       Date:  2002-06       Impact factor: 4.512

9.  Chromosomal Density of Cancer Up-Regulated Genes, Aberrant Enhancer Activity and Cancer Fitness Genes Are Associated with Transcriptional Cis-Effects of Broad Copy Number Gains in Colorectal Cancer.

Authors:  Daniele Filippo Condorelli; Anna Provvidenza Privitera; Vincenza Barresi
Journal:  Int J Mol Sci       Date:  2019-09-19       Impact factor: 5.923

10.  The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia.

Authors:  Sanne Noort; Priscilla Wander; Todd A Alonzo; Jenny Smith; Rhonda E Ries; Robert B Gerbing; M Emmy M Dolman; Franco Locatelli; Dirk Reinhardt; Andre Baruchel; Jan Stary; Jan J Molenaar; Ronald W Stam; Marry M van den Heuvel-Eibrink; Michel C Zwaan; Soheil Meshinchi
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

View more
  2 in total

1.  Molecular Mechanisms and Therapies of Myeloid Leukaemia.

Authors:  Elliott Brown; Barbara-Ann Guinn
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 2.  SPINKs in Tumors: Potential Therapeutic Targets.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Minglin Zhang; Jie Chen; Xiaolan Li; Linlin Xiao; Jiajia Wang; Qian Long; Jianguo Liu; Xiaoyan Guan
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.